Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 1.00 |
| ▸ | MAOB | P27338 | 4/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.83 |
| ▸ | HPGD | P15428 | 6/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.83 |
| ▸ | CTSD | P07339 | 1/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.83 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.83 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.83 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ilepcimide SCHEMBL30887538 | 1.00 | NPC1 (1.00) | NPC1RAB9ATRPV1MAOBKDM4E | |
| Ilepcimide SCHEMBL30237912 | 1.00 | NPC1 (1.00) | NPC1RAB9ATRPV1MAOBKDM4E | |
| Ilepcimide SCHEMBL29738474 | 1.00 | NPC1 (1.00) | NPC1RAB9ATRPV1MAOBKDM4E | |
| Ilepcimide SCHEMBL3838030 | 1.00 | NPC1 (1.00) | NPC1RAB9ATRPV1MAOBKDM4E | |
| SCHEMBL3115705 | 0.99 | MAOB (1.00) | NPC1RAB9ATRPV1MAOBKDM4E | |
| SCHEMBL3115704 | 0.99 | MAOB (1.00) | NPC1RAB9ATRPV1MAOBKDM4E | |
| SCHEMBL10793053 | 0.93 | MAOB (0.90) | NPC1RAB9ATRPV1MAOBKDM4E | |
| SCHEMBL10793048 | 0.93 | MAOB (0.90) | NPC1RAB9ATRPV1MAOBKDM4E | |
| Piperine SCHEMBL5309092 | 0.91 | MAOB (1.00) | NPC1RAB9ATRPV1MAOBKDM4E | |
| SCHEMBL17340450 | 0.91 | MAOB (1.00) | NPC1RAB9ATRPV1MAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3687311-A1 | AMIDES FOR GENERATING A TRIGEMINAL EFFECT | Symrise AG (DE) | 2020-08-05 | — | — | EP | claimed |
| CN-109867656-A | A kind of preparation method of Ilepcimide | 北京斯利安药业有限公司 | 2019-06-11 | — | — | CN | claimed |
| WO-2019063069-A1 | AMIDES FOR GENERATING A TRIGEMINAL EFFECT | SYMRISE AG (DE) | 2019-04-04 | — | — | WO | claimed |
| CN-105193803-B | A kind of Ilepcimide sustained release preparation and preparation method thereof | 北京斯利安药业有限公司 | 2019-02-19 | — | — | CN | claimed |
| CN-107998092-A | Medicament slow release unit, Orally disintegrating sustained release tablets comprising the medicament slow release unit and its preparation method and application | 上海宣泰医药科技有限公司 | 2018-05-08 | — | — | CN | claimed |
| CN-105193803-A | Ilepcimide sustained release preparation and preparation method thereof | BEIJING SCRIANEN PHARMACEUTICAL CO LTD | 2015-12-30 | — | — | CN | claimed |
| CN-104940930-A | Oral medicine emulsion for treating pediatric epilepsy, and preparation method thereof | HEILONGJIANG BAITONG CHILDREN MEDICINE RES CO LTD | 2015-09-30 | — | — | CN | claimed |
| CN-104922057-A | Child-type oral anti-epileptic pharmaceutical gel unit and preparation method thereof | HEILONGJIANG BAITONG CHILDREN S MEDICINES RES CO LTD | 2015-09-23 | — | — | CN | claimed |
| EP-2918271-A1 | Aromatic alkenoic acid derivatives as aroma compounds | Symrise AG (DE) | 2015-09-16 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101808635-A | Use of piperine and derivatives thereof for the therapy of neurological conditions | SYGNIS BIOSCIENCE GMBH & CO KG | 2010-08-18 | — | — | CN | claimed |
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYNGIS Bioscience GmbH & Co. KG (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2170320-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | Sygnis Bioscience GmbH & Co. KG (DE) | 2010-04-07 | — | — | EP | claimed |
| WO-2009004071-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | SYGNIS BIOSCIENCE GMBH & CO. KG (DE) | 2009-01-08 | — | — | WO | claimed |
| EP-2011495-A1 | Use of piperine and derivatives thereof for the therapy of neurological conditions | Sygnis Bioscience GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179130-A1 | USE OF PIPERINE AND DERIVATIVES THEREOF FOR THE THERAPY OF NEUROLOGICAL CONDITIONS | PRPH, BDNF, GAP43 | NPC1 725/4885RAB9A 803/4885TRPV1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.